| Name | Title | Contact Details |
|---|---|---|
Muddassar Shaikh |
VP of Software Engineering | Profile |
Kevin Pawloski |
VP, Information Security and Compliance | Profile |
Jody Mulkey |
Chief Technology Officer | Profile |
Making an impact on rare and serious skin and connective tissue diseases Fibrocell Science is at the forefront of the exciting and promising field of personalized biologics. By extracting cells from skin to create localized therapies that are compatible with the unique biology of each patient, personalized biologics bring a transformational approach to drug development. It is Fibrocell’s scientific leadership and legacy in cultivating and harnessing autologous fibroblast cells that fuels its personalized biologics approach. Fibrocell’s proprietary technology uses a person’s own fibroblast cells – with or without genetic modification – to target localized treatment of rare and serious skin and connective tissue diseases.
Georgia Cancer Specialists is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Georgia Cancer Specialists is based in Atlanta, GA. You can find more information on Georgia Cancer Specialists at www.gacancer.com
Bio Research Associates is a Milwaukee, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pioneering skin cancer tools for you and your family. DermaSensor is designing an affordable handheld sensor device that will let you scan your skin for irregular lesions in seconds.
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.